Temple Health to Present New Data on Patient-Specific Subcutaneous Insulin Dosing at DTM 2025

As the healthcare community gathers for the 2025 Diabetes Technology Society (DTS) meeting, a highly anticipated poster presentation from Temple University Health System and the Lewis Katz School of Medicine is set to highlight new evidence supporting patient-specific insulin dosing for hospitalized patients.

While the full results remain under embargo until the official presentation on Tuesday 28th October at 4.30pm (PST), the poster – “Safety and Efficacy of a Patient-Specific Inpatient Dosing Application for Subcutaneous Insulin” – will share outcomes from Temple’s use of EndoTool SubQ – a computerized, patient-specific dosing application for patients requiring subcutaneous insulin.

Led by Ajay Rao, MD, MMSc, Section Chief, Endocrinology, Diabetes and Metabolism, Lewis Katz School of Medicine at Temple University, with collaborators David Fleece, MD; Paul D. Chidester, MD, FACP; and Anderson Schrader, MEng, the study builds upon Temple’s prior findings demonstrating exceptional safety and precision of patient-specific dosing in the IV setting.

This new analysis evaluates whether similar results like those achieved with EndoTool IV (ETIV) can be achieved with EndoTool SubQ (ETSQ) – a computerized subcutaneous insulin dosing application designed to individualize therapy across inpatient settings.

Why it Matters

With new CMS glycemic management measures taking effect in 2026, hospitals nationwide are prioritizing solutions that improve inpatient glucose control and reduce preventable harm.

Temple’s findings come at a critical time, offering timely data on how patient-specific dosing can reduce both severe hypoglycemia and hyperglycemia while ensuring safety in high-risk populations.

Join Us at DTM 2025

Our team will be onsite at the Glooko booth throughout the DTM meeting to discuss patient-specific insulin dosing for inpatient populations and share how hospitals are using EndoTool to improve glycemic safety and efficiency.

The full Temple Health data will be unveiled during the conference, with a summary of findings available here following the embargo lift.

Poster Presentation:

Safety and Efficacy of a Patient-Specific Inpatient Dosing Application for Subcutaneous Insulin

Authors: Ajay Rao, MD, MMSc; David Fleece, MD; Paul D. Chidester, MD, FACP; Anderson Schrader, MEng

Affiliation: Temple University Health System and Lewis Katz School of Medicine at Temple University, Philadelphia, PA USA

Conference: Diabetes Technology Society (DTS) 2025 Annual Meeting

About EndoTool

EndoTool is developed and marketed by Monarch Medical Technologies, a Glooko Company, and is FDA-cleared for use by healthcare professionals in inpatient care settings.